[go: up one dir, main page]

AR056187A1 - Derivados de imidazo[1,2-a)piridina: preparacion, composiciones farmaceuticas y uso para preparar medicamentos - Google Patents

Derivados de imidazo[1,2-a)piridina: preparacion, composiciones farmaceuticas y uso para preparar medicamentos

Info

Publication number
AR056187A1
AR056187A1 ARP060101088A ARP060101088A AR056187A1 AR 056187 A1 AR056187 A1 AR 056187A1 AR P060101088 A ARP060101088 A AR P060101088A AR P060101088 A ARP060101088 A AR P060101088A AR 056187 A1 AR056187 A1 AR 056187A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
alkenyl
optionally substituted
heterocycloalkyl
Prior art date
Application number
ARP060101088A
Other languages
English (en)
Original Assignee
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltd filed Critical S Bio Pte Ltd
Publication of AR056187A1 publication Critical patent/AR056187A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

Los compuestos de hidroximato son inhibidores de histona deacetilasa. Se divulgan compuestos de imidazo[1,2-a]piridina y métodos para su preparacion. Estos compuestos pueden ser utiles como medicamentos para el tratamiento de trastornos proliferativos así como enfermedades relacionadas o asociadas con enzimas que tienen actividad de histona deacetilasa (HDAC). Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), en donde R1 está seleccionado del grupo que consiste en H, halogeno, -CN, -NO2, -CF3, -OCF3, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, heteroalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo, arilalquenilo, cicloalquilheteroalquilo, arilheteroalquilo, heterocicloalquilheteroalquilo, heteroarilheteroalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, alcoxiarilo, alqueniloxi, alquiniloxi, cicloalquiloxi, heterocicloalquiloxi, ariloxi, heteroariloxi, arilalquiloxi, fenoxi, benciloxi, amino, alquilamino, aminoalquilo, acilamino, arilamino, sulfonilamino, sulfinilamino, -COOH, - COR5, -COOR5, -CONHR5, -NHCOR5, -NHCOOR5, - NHCONHR5, C(=NOH)R5, - alquilNCOR5, alcoxicarbonilo, alquilaminocarbonilo, sulfonilo, alquilsulfonilo, alquilsulfinilo, arilsulfonilo, arilsulfinilo, aminosulfonilo, SR6 y acilo, cada uno de los cuales puede estar opcionalmente substituido; o R1 = L; R2 está seleccionado del grupo que consiste en H, halogeno, -CN, -NO2, -CF3, -OCF3, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, heteroalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo, arilalquenilo, cicloalquilheteroalquilo, arilheteroalquilo, heterocicloalquilheteroalquilo, heteroarilheteroalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, alcoxiarilo, alqueniloxi, alquiniloxi, cicloalquiloxi, heterocicloalquiloxi, ariloxi, heteroariloxi, arilalquiloxi, fenoxi, benciloxi, amino, alquilamino, aminoalquilo, acilamino, arilamino, sulfonilamino, sulfinilamino, -COOH, - COR5, -COOR5, -CONHR5, -NHCOR5, -NHCOOR5, -NHCONHR5, C(=NOH)R5, - alquilNCOR5, alcoxicarbonilo, alquilaminocarbonilo, sulfonilo, alquilsulfonilo, alquilsulfinilo, arilsulfonilo, arilsulfinilo, aminosulfonilo, SR6 y acilo, cada uno de los cuales puede estar opcionalmente substituido; o R2 = L; R3 está seleccionado del grupo que consiste en H, alquilo, alquenilo, alquinilo, haloalquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo y acilo cada uno de los cuales puede estar opcionalmente substituido; R4 está seleccionado del grupo que consiste en H, alquilo, alquenilo, alquinilo, haloalquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo y acilo cada uno de los cuales puede estar opcionalmente substituido; cada Y está seleccionado de modo independiente del grupo que consiste en H, halogeno, -CN, -NO2, -CF3, -OCF3, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, haloalquinilo, heteroalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, alcoxiarilo, alcoxiheteroarilo, alqueniloxi, alquiniloxi, cicloalquiloxi, cicloalqueniloxi, heterocicloalquiloxi, heterocicloalqueniloxi, ariloxi, heteroariloxi, arilalquilo, heteroarilalquilo, arilalquiloxi, amino, alquilamino, acilamino, aminoalquilo, arilamino, sulfonilo, alquilsulfonilo, arilsulfonilo, aminosulfonilo, aminoalquilo, alcoxialquilo, -COOH -C(O)OR6, -COR6, -SH, - SR7, -OR7, acilo y -NR8R9 cada uno de los cuales puede estar opcionalmente substituido; cada R5 está seleccionado de modo independiente del grupo que consiste en H, alquilo, alquenilo, alquinilo, haloalquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo y acilo cada uno de los cuales puede estar opcionalmente substituido; cada R6 está seleccionado de modo independiente del grupo que consiste en H, alquilo, alquenilo, alquinilo, haloalquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo y acilo cada uno de los cuales puede estar opcionalmente substituido; cada R7 está seleccionado de modo independiente del grupo que consiste en H, alquilo, alquenilo, alquinilo, haloalquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo y acilo cada uno de los cuales puede estar opcionalmente substituido; cada R8 y R9 está seleccionado de modo independiente del grupo que consiste en H, alquilo, alquenilo, alquinilo, haloalquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo y acilo cada uno de los cuales puede estar opcionalmente substituido; p es un entero seleccionado del grupo que consiste en 0, 1, 2 y 3; L está seleccionado del grupo que consiste en a) Cy-L1-W-; b) Cy-L1-W-L2-; c) Cy-(CH2)k-W-; d) L1-W-L2-; e) Cy-L1-; f) R12-W1-L1-W-; y g) -(CR20R21)m-(CR22R23)n-(CR24R25)o-NR26R27; en donde Cy está seleccionado del grupo que consiste en alquilo C1-15, aminoalquilo, heteroalquilo, heterocicloalquilo, cicloalquilo, arilo, ariloxi y heteroarilo, cada uno de los cuales puede estar opcionalmente substituido; L1 está seleccionado del grupo que consiste en un enlace, alquilo C1-5 y alquenilo C2-5, cada uno de los cuales puede estar opcionalmente substituido; L2 está seleccionado del grupo que consiste en alquilo C1-5 y alquenilo C2-5, cada uno de los cuales puede estar opcionalmente substituido; k es 0, 1, 2, 3, 4 o 5; W está seleccionado del grupo que consiste en un enlace, - O-, -S-, -S(O)-, -S(O)2-, -N(R10)-, -C(O)N(R10)-, -SO2N(R10)-, -N(R10)C(O)-, -N(R10)SO2-, -N(R10)C(O)N(R11)-, -C(O)N(R10)C(O)N(R11)- y -N(R10)C(O)N(R11)C(O)-; W1 está seleccionado del grupo que consiste en un enlace, -O-, -S-, -S(O)-, -S(O)2-, - N(R10)-, -C(O)N(R10)-, -SO2N(R10)-, -N(R10)C(O)-, -N(R10)SO2-, -N(R10)C(O)N(R11)-, -C(O)N(R10)C(O)N(R11)- y -N(R10)C(O)N(R11)C(O)-; cada R20, R21, R22, R23, R24 y R25 está seleccionado de modo independiente del grupo que consiste en H, halogeno, - CN, -NO2, -CF3, -OCF3, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, haloalquinilo, heteroalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo, arilalquenilo, cicloalquilheteroalquilo, heterocicloalquilheteroalquilo, heteroarilheteroalquilo, arilheteroalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, alcoxiarilo, alcoxiheteroarilo, alqueniloxi, alquiniloxi, cicloalquiloxi, heterocicloalquiloxi, ariloxi, arilalquiloxi, fenoxi, benciloxi heteroariloxi, amino, alquilamino, acilamino, aminoalquilo, arilamino, alcoxicarbonilo, alquilaminocarbonilo, sulfonilo, alquilsulfonilo, aminosulfonilo, arilsulfonilo, arilsulfinilo -COOH, -C(O)OR5, - COR5, -SH, -SR6, -OR6 y acilo, cada uno de los cuales puede estar opcionalmente substituido; o R20 y R21 cuando se toman juntos pueden formar un grupo de la formula =O o =S, y/o R22 y R23 cuando se toman juntos pueden formar un grupo de la formula =O o =S, y/o R24 y R25 cuando se toman juntos pueden formar un grupo de la formula =O o =S; cada R26 y R27 está seleccionado de modo independiente del grupo que consiste en H, halogeno, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, heteroalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo, arilalquenilo, cicloalquilheteroalquilo, heterocicloalquilheteroalquilo, heteroarilheteroalquilo, arilheteroalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, alcoxiarilo, alqueniloxi, alquiniloxi, cicloalquiloxi, heterocicloalquiloxi, ariloxi, arilalquiloxi, heteroariloxi, amino, alquilamino, aminoalquilo, acilamino, arilamino, fenoxi, benciloxi, COOH, alcoxicarbonilo, alquilaminocarbonilo, sulfonilo, alquilsulfonilo, alquilsulfinilo, arilsulfonilo, arilsulfinilo, aminosulfonilo, SR5, acilo y G, cada uno de los cuales puede estar opcionalmente substituido o R26 y R27 cuando se toman junto con el átomo de nitrogeno al que están unidos, forman un grupo heterocicloalquilo o heteroarilo, cada uno de los cuales puede estar opcionalmente substituido; m, n y o son cada uno enteros que están seleccionados de modo independiente del grupo que consiste en 0, 1, 2, 3 y 4; G es un grupo de formula -L3W3, en donde L3 está seleccionado del grupo que consiste en alquilo C1-5 y alquenilo C2-5, cada uno de los cuales puede estar opcionalmente substituido; W3 está seleccionado del grupo que consiste en un enlace, -OR12, -SR12, -S(O)R12, -S(O)2R12, -N(R12)2, -C(O)N(R12)2, -SO2N(R12)2, -NR12C(O)-, -NR12SO2R12, - NR12C(O)N(R12)2, -C(O)NR12C(O)N(R12) y -N(R12)C(O)N(R12)C(O)R12; R10 y R11 son iguales o diferentes y están está seleccionados de modo independiente de H, alquilo C1-6, alquenilo C1-6, heteroalquilo C1-10, cicloalquilo C4-9, heterocicloalquilo C4-9, arilo, heteroarilo, arilalquilo, y heteroarilalquilo y acilo cada uno de los cuales puede estar opcionalmente substituido; R12 está seleccionado del grupo que consiste en H, halogeno, -CN, -NO2, -CF3, -OCF3, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, heteroalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo, arilalque
ARP060101088A 2005-03-21 2006-03-20 Derivados de imidazo[1,2-a)piridina: preparacion, composiciones farmaceuticas y uso para preparar medicamentos AR056187A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66326505P 2005-03-21 2005-03-21
US75954406P 2006-01-18 2006-01-18

Publications (1)

Publication Number Publication Date
AR056187A1 true AR056187A1 (es) 2007-09-26

Family

ID=37024054

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101088A AR056187A1 (es) 2005-03-21 2006-03-20 Derivados de imidazo[1,2-a)piridina: preparacion, composiciones farmaceuticas y uso para preparar medicamentos

Country Status (12)

Country Link
EP (1) EP1863811B1 (es)
JP (1) JP5206405B2 (es)
KR (1) KR101300831B1 (es)
CN (1) CN101218238B (es)
AR (1) AR056187A1 (es)
AU (1) AU2006225355B2 (es)
CA (1) CA2602328C (es)
ES (1) ES2470766T3 (es)
MX (1) MX2007011710A (es)
MY (1) MY147647A (es)
TW (1) TW200714600A (es)
WO (1) WO2006101455A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
WO2008029152A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2064211B1 (en) * 2006-09-20 2015-11-11 MEI Pharma, Inc. Imidazo[1,2-a]pyridine hydroxymate compounds that are inhibitors of histone deacetylase
EP2096923B1 (en) 2006-11-27 2014-01-22 H. Lundbeck A/S Heteroaryl amide derivatives
WO2008068392A1 (fr) * 2006-12-07 2008-06-12 Commissariat A L'energie Atomique Nouveaux derives fluorophores imidazo [1,2-a] pyridin-3-yl-amine et leur procede de preparation
CN101772498A (zh) 2007-04-10 2010-07-07 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物
WO2008134553A1 (en) * 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
JP2010526836A (ja) * 2007-05-10 2010-08-05 ジーイー・ヘルスケア・リミテッド カンナビノイドＣＢ２レセプターに対して活性を有するイミダゾール（１，２−ａ）ピリジン及び関連化合物
US8481572B2 (en) 2007-08-09 2013-07-09 Urifer Ltd. Pharmaceutical compositions and methods for the treatment of cancer
DE102007040336A1 (de) 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
JP2011502133A (ja) * 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
EP2300470A2 (en) * 2008-05-19 2011-03-30 Sepracor Inc. Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
WO2010032195A1 (en) * 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
WO2010043953A2 (en) * 2008-10-15 2010-04-22 Orchid Research Laboratories Ltd. Novel bridged cyclic compounds as histone deacetylase inhibitors
CA2807230A1 (en) * 2010-08-03 2012-02-09 The Regents Of The University Of California Compounds and compositions for mitigating tissue damage and lethality
WO2012105594A1 (ja) 2011-02-01 2012-08-09 協和発酵キリン株式会社 縮環複素環誘導体
JP2014509616A (ja) * 2011-03-31 2014-04-21 エーエムベーエルエーエム テクノロジー トランスファー ゲーエムベーハー 治療用イミダゾ［１，２−ａ］ピリジン化合物
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2014021383A1 (ja) * 2012-07-31 2014-02-06 協和発酵キリン株式会社 縮環複素環化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
KR20160002839A (ko) * 2013-04-30 2016-01-08 에프. 호프만-라 로슈 아게 피라졸 아마이드의 Pd-촉진된 커플링
SG11201509650YA (en) * 2013-05-24 2015-12-30 Iomet Pharma Ltd Slc2a transporter inhibitors
MX363456B (es) 2013-06-25 2019-03-25 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal.
WO2015058106A1 (en) 2013-10-18 2015-04-23 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
WO2017030938A1 (en) * 2015-08-14 2017-02-23 Incyte Corporation Heterocyclic compounds and uses thereof
KR101850062B1 (ko) * 2016-09-08 2018-04-19 가천대학교 산학협력단 신규 스피로퀴논 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 신경계 질환의 예방 또는 치료용 약학적 조성물
EP4019607B1 (en) 2020-12-22 2024-05-15 Essilor International Electrochromic compounds and optical articles containing them
CN113321651B (zh) * 2021-06-22 2022-06-14 四川省医学科学院·四川省人民医院 吡唑并吡啶异羟肟酸类化合物、其制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221996A (en) 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
WO1996034866A1 (en) * 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
IL139166A0 (en) * 1998-05-20 2001-11-25 Lilly Co Eli Anti- viral compounds
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
TW200501897A (en) 2003-07-10 2005-01-16 Kung-Sheng Pan Shoes electrostatically embedded with objects
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
WO2005085214A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd ジアリール置換複素５員環誘導体
AU2005223389A1 (en) * 2004-03-17 2005-09-29 Altana Pharma Ag 7H-8,9-dihydro-pyrano (2,3-C) imidazo (1,2a) pyridine derivatives and their use as gastric acid secretion inhibitors

Also Published As

Publication number Publication date
AU2006225355A1 (en) 2006-09-28
TW200714600A (en) 2007-04-16
KR20080005207A (ko) 2008-01-10
CN101218238A (zh) 2008-07-09
CA2602328A1 (en) 2006-09-28
KR101300831B1 (ko) 2013-08-30
CA2602328C (en) 2014-07-29
ES2470766T3 (es) 2014-06-24
JP5206405B2 (ja) 2013-06-12
EP1863811A1 (en) 2007-12-12
EP1863811A4 (en) 2008-11-12
MY147647A (en) 2012-12-31
MX2007011710A (es) 2007-11-20
AU2006225355B2 (en) 2010-12-09
JP2008533198A (ja) 2008-08-21
EP1863811B1 (en) 2014-03-12
WO2006101455A1 (en) 2006-09-28
CN101218238B (zh) 2011-10-26

Similar Documents

Publication Publication Date Title
AR056187A1 (es) Derivados de imidazo[1,2-a)piridina: preparacion, composiciones farmaceuticas y uso para preparar medicamentos
AR046920A1 (es) Hidroxamatos conectados a acilurea y conectado a sulfonilurea
AR046605A1 (es) Hidroxamatos unidos a biarilo; preparacion y aplicaciones farmaceuticas
AR055364A1 (es) Derivados de benzimidazol
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
MY148076A (en) New sulfonamide derivatives as bradykinin antagonists
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
NO992935L (no) Sulfonamid og karboksamid-derivater og legemidler inneholdende de samme som det aktive ingrediens
KR870007137A (ko) 치환 피리딘술폰아미드 화합물, 이들을 함유하는 제초 조성물 및 이들 화합물의 제조 방법.
AR080263A1 (es) Inhibidores ns5a de vhc
ZA200204188B (en) Substituted oxazolidinones and their use in the field of blood coagulaton.
RU2008152180A (ru) ПРОИЗВОДНЫЕ ПИРРОЛА, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ CRTh2 РЕЦЕПТОРА
IL167714A (en) Aryl sulfonamides and uses thereof for modulation of ccr9
CR20190039A (es) ACETAMIDAS SUSTITUIDAS POR N-(HETERO)-ARILO Y 2-(HETERO)-ARILO (Divisional 2011-0520)
JP2012510993A5 (es)
JP2020536863A5 (es)
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
NO20065929L (no) Sykliske amidderivater, deres fremstilling og anvendelse
NO20090952L (no) N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
AR041190A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoacetico sustituidas
DK1981874T3 (da) Aminophenylderivater som nye inhibitorer af histondeacetylase
AR019427A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa, procedimiento para su preparacion, su uso para la preparacion de medicamentos, composiciones farmaceuticas y compuestos intermediarios utiles para su preparacion
AR105930A2 (es) Derivados de benzimidazol
EP4118221A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING 2,5-FURAN DICARBOXYLIC ACID

Legal Events

Date Code Title Description
FB Suspension of granting procedure